Why Sustainable Biomanufacturing Must Start Earlier in The Process
LYMPHOMA TREATMENT AT A CROSSROADS
Clinically Validated Probiotics
The Emergence of 3D Printing in Expanding Clinical Research and Pharmaceutical Compounding
Two Acts, One Geopolitical Moment
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
GE Healthcare
President & CEO
Our current business focus and strengths are in the areas of bioprocessing proteins cellular analysis cell handling and tools for cell therapy Our strategic intent is to add adjacent technologies or applications which can add value to the overall customer solutions we provide
We are particularly excited about the sample collection and storage opportunity with the FTA product lineWe have a stron...
Articles
Incipient Biopharmaceutical Claims of Milk Derived Exosomes
Exosomes are bilayer nanoextracellular vehicles EVs that areproduced by endocytosis in mammalian cells Under physiological conditions they are involved in intercellular communication viaproteins lipids and RNAs With a size distribution of nm exosomes have been identified in various biofluids
Research Insights
Role of sTREM-1 in predicting mortality of infection: a systematic review and meta-analysis
Abstract Objectives Several studies have investigated the prognostic value of soluble triggering receptor expressed on myeloid cells sTREM in patients with infection However the result was controversial Thus the purpose of the present metaanalysis was to determine the prognostic value of the sTREM
Case Studies
Local Production Of Pharmaceuticals And Related Technology Transfer In Developing Countries
Abstract As stakeholders in the Global Strategy and Plan of Action on Public Health Innovation and Intellectual Property GSPAPHI adopted by the World Health Assembly in the United Nations Conference on Trade and Development UNCTAD the World Health Organization WHO and the International Centre for Trade and Sustainable Development ICTSD are col
Techno Trends
Novel Repotrectinib Therapeutic Option Discovered for Advanced Solid Tumors
Turning Point Therapeutics Inc discovered novel repotrectinib a leading drug candidate for the treatment of patients with advanced solid tumors having an NTRK gene fusion Repotrectinib is a therapeutic option for patients who have shown progress with or prior TRK TKIs after treatment with or without prior chemotherapy
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Labelling and imaging of Radiopharmaceuticals
Sumel Ashique has been working as an assistant professor in Bengal College of Pharmaceutical Sciences & Research, Durgapur 713212, West Bengal, India. He has 3.5 years of teaching experience. He has achieved 50+ publications of International and national accredited reputed journals (Scopus, UGC). He has knowledge in drug delivery, nanotechnology and targeted treatment strategy. He has also 4 granted patents from IP and Australia, 8 published book chapters in International Books and 12 book chapters have been submitted to well-known publishers like Springer, Elsevier, Bentham and Taylor & Francis. Currently he is editing 5 books under CRC; AAP, Springer and Wiley publisher
Radheshyam Pal is an Assistant Professor at Pandaveswar School of Pharmacy. His areas of expertise in Neuropharmacology. He specifically works on the role of natural products in the CNS. He has 2 years of teaching experience. He has 2 patents and also 10 book chapters submitted in international publisher.
Evolution of eCTD from version 1 to 4
Gouspasha is a seasoned professional with 12 years of experience in the pharmaceutical industry, specializing in eCTD (Electronic Common Technical Document) publishing and submission. With a strong focus on regulatory compliance and efficient document management, Gouspasha ensures seamless and timely submissions. Dedicated to maintaining the highest standards of quality and accuracy, Gouspasha remains committed to staying current with evo0lving industry trends and regulatory requirements.
Tiny Vesicles, Big Impact
Dr. Disha Marwaha received her PhD in biological sciences from CSIR-Central Drug Research Institute (CSIR-CDRI), India in 2024. She is currently an Assistant Professor at the GLA University, Mathura. She has more than 20 publications in international peer-reviewed Journals. She is an expert in formulation and development, nanomedicine and pharmacokinetics focusing on innovative therapeutic and targeted drug delivery systems.
Dr. Neha Singh received her Ph.D. in Biological Sciences from the CSIR-Central Drug Research Institute (CSIR-CDRI), India, in 2025. She is currently an Assistant Professor at the Lloyd School of Pharmacy, Greater Noida. Dr. Singh has contributed extensively to the field of pharmaceutical sciences, with many publications, patents, and book chapters in internationally recognised peer-reviewed journals. Her primary research interests include formulation development, nanomedicine and pharmacokinetics, with a focus on innovative therapeutic strategies and targeted drug delivery systems. Dr. Singh’s work reflects her commitment to advancing precision medicine and developing next-generation solutions for healthcare.
The Unknown Sources of Error in the Pharmaceutical Weighing Process
Thomas Caratsch has been the Head of Laboratory Division since December 2007 at the company's headquarters in Greifensee, Switzerland. Prior to joining the company, Caratsch held various management positions within the Hoffmann La Roche group in the U.S. and Switzerland, including General Manager of Roche Instrument Centre AG and Head of Disetronic Medical Systems AG. He began his career as a development engineer at Sodeco-Saia in Geneva.
Nanotechnology as a Potential Therapeutic Strategy in Breast Cancer Management
Mr. Rahul Pal (Young Scientist), Ass. Prof. Department of Pharmacy, Jagannath University, Jaipur, holds B. Pharm, M. Pharm (Pharmaceutics), and PhD* at Chitkara University. He has authored 50+ publications, 8 textbooks, 12 edited book, secured 38 patents, 3 copyrights, received the Young Researcher Award (2025), and actively contributes as reviewer, editor, and speaker in national and international academic forums.
press releasesRead more...
Merck Opens €300 Million Asia-Pacific Bioprocessing Center in Daejeon, South Korea
Merck a leading science and technology company today opened its new AsiaPacific Bioprocessing Production Center in Daejeon South Korea The center represents an investment of more than million the companys largest Life Science investment in AsiaPacific to date
Flagship Pioneering Forms Etcelera to Move Drug Discovery from Probability to Prediction
Flagship Pioneering a scientific innovation engine for transformative platforms and products today announced the formation of Etcelera a company created by the merger of the platforms of Cellarity Cellarity Platform Inc Etiome and Empress Therapeutics to pioneer causal intelligence in human biology...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased
Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL
Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders
EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific
EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company
EventsRead more...
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
LATEST NEWSRead more...
Edison Scientific Enters into Agreement with Pfizer to Advance Drug Research and Development
Edison Scientific has entered into an agreement with Pfizer to introduce its Edison AI Platform and AI scientist Kosmos across Pfizers biopharmaceutical research and development activities The collaboration will combine Edison Scientifics artificial intelligence AI technology with Pfizers scientific...
Appian and PSI CRO Partner to Advance AI-driven Clinical Trial Operations
Appian and PSI CRO have entered into a strategic partnership to introduce an artificial intelligence AIpowered solution for clinical trial site identification and selection The solution is now live and is designed to automate site selection across different therapeutic areas medical conditions and...
Adalvo Acquires Romiplostim Biosimilar from Enzene
Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...
Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation
Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
